A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA
All the currently used type A botulinum neurotoxins for clinical uses are of subtype A1. We compared the efficacy and safety for the first time head-to-head between a novel botulinum toxin A2NTX prepared from subtype A2 and onabotulinumtoxinA (BOTOX) derived from A1 for post-stroke spasticity. We as...
Main Authors: | Ryuji Kaji, Ai Miyashiro, Nori Sato, Taiki Furumoto, Toshiaki Takeuchi, Ryosuke Miyamoto, Tomoko Kohda, Yuishin Izumi, Shunji Kozaki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/14/11/739 |
Similar Items
-
OnabotulinumtoxinA: Still the Present for Chronic Migraine
by: Carlo Baraldi, et al.
Published: (2023-01-01) -
Pericranial Muscle Stiffness, Pain Thresholds, and Tenderness during a Treatment Cycle of OnabotulinumtoxinA for Chronic Migraine Prevention
by: Sebastian Worsaae Dalby, et al.
Published: (2024-02-01) -
Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility
by: Chung-Cheng Wang, et al.
Published: (2016-03-01) -
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
by: Aubrey Manack Adams, et al.
Published: (2023-08-01) -
Real Life Data on OnabotulinumtoxinA for Treatment of Chronic Migraine in Pediatric Age
by: Laura Papetti, et al.
Published: (2023-02-01)